ESTROMON (Generic of Premarin)

Conjugate Estrogens 0.6 25 mg 1 BOX

Size : 10 packs or 100 Tablets per Box

Are a hormone replacement therapy (HRT) used to manage moderate to severe vasomotor symptoms associated with menopause. Also indicated in atrophic vaginitis, vulvar kraurosis, hypogonadism and female castration and primary chronic failure. Conjugated estrogens used in conjunction with other therapeutic measures (eg diet, calcium, physical therapy) to retard osteoporosis associated with estrogen deficiency in menopausal women.

ACTIVE INGREDIENT: Conjugate Estrogens 0.625mg

DESCRIPTION:

It occurs as a pink round bi­convex tablet with a diameter 6.5 mm. engraved “S” script on one side and the other side is smooth

ACTINS AND MODE OR MECHANISMS OF ACTION: Metabolic and Somatic Effects: Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sex characteristics. Estrogens cause growth and development of the vagina, uterus and fallopian tubes, and the enlargement of the breasts. Indirectly, estrogens contribute to the shaping of the skeleton, maintenance of tone and elasticity of urogenital structures, cause changes in the epiphyses of the long bones producing pubertal growth spurt and termination, axillary and pubic hair growth, and pigmentation of the nipples and genitals. In rolonged estrogen deficiency states, the administration of estrogens may alter associated degenerative bone changes. Effect on Menstruation: An ebb and rise of the female gonadal hormone produces the normal menstrual cycle. Indirect effect of

estrogen to induce ovulation is produced by negative feedback at Hypothalamus and Pituitary gland which increases LH levels and induce ovulation. Estrogen levels rise during the first half of the menstrual cycle. At midpoint in the second half of the cycle, the corpus luteum produces high levels of both estrogens and progesterone. Decline of estrogenic activity at the end of the menstrual cycle commonly brings on menstruation, although the cessation of progesterone secretion is the most important factor in this phase of the mature ovulatory cycle. Effects on Nervous System: Estrogens also affect the psychologic and emotional aspects of feminine behavior. As estrogen levels increase during the menstrual cycle, women experience a sense of wellbeing and vigor. In the postmenopausal period, after the decline of endogenous estrogen production, estrogen administration aids in relieving nervous symptoms, such as anxiety, depression and irritability.

INDICATIONS:

1. Relief of menopausal and postmenopausal symptoms occurring in naturally or surgically induced estrogen deficiency states including vulvar and vaginal atrophy. 2. Prevention and treatment of osteoporosis in naturally occurring or surgically induced estrogen­deficiency states. This is in addition to other important therapeutic measures eg. adequate diet and regular exercise. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered to be appropriate. 3. Hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. Atrophic vaginitis. 5. Vulvar atrophy (with or without pruritis).

STORAGE CONDITIONS. USER INSTRUCTIONS AND PHARMACEUTICAL PRECAUTIONS: Store in well­closed container and at room temperature below 25°C